Associated Papers
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8.
Toribio-Castelló S et al.
Cancers, 2023
37568638 (PubMed )
Supplement: cancers-15-03822-s001.zip › Supplementary_tables.xlsx › Table_S2
Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome.
Fang Y et al.
Frontiers in Oncology, 2020
33520721 (PubMed )
Supplement: Table_2.xlsx › Sheet1
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.
Aldoss I et al.
Haematologica, 2017
28971906 (PubMed )
Supplement: 2017.172544.ALDOSS_SUPPL.pdf
Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing.
Xu Y et al.
Oncotarget, 2017
29137279 (PubMed )
Supplement: oncotarget-08-82475-s003.xls › Sheet1
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.
Li S et al.
Nature Medicine, 2016
27322744 (PubMed )
Supplement: NIHMS786454-supplement-7.xlsx › Sheet1
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
Merlevede J et al.
Nature Communications, 2016
26908133 (PubMed )
Supplement: ncomms10767-s2.xls › Feuille1
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Zhao LJ et al.
Blood, 2012
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.
Dicker F et al.
Blood, 2007
Select a paper to view details